Santa Maria Peter Luke, Kim Sungwoo, Varsak Yasin Kursad, Yang Yunzhi Peter
1 Department of Otolaryngology, Head and Neck Surgery, Stanford University , Stanford, California.
Tissue Eng Part A. 2015 May;21(9-10):1483-94. doi: 10.1089/ten.TEA.2014.0474. Epub 2015 Mar 17.
We aim to explore the role of epidermal growth factor (EGF) ligand shedding in tympanic membrane wound healing and to investigate the translation of its modulation in tissue engineering of chronic tympanic membrane perforations. Chronic suppurative otitis media (CSOM) is an infected chronic tympanic membrane perforation. Up to 200 million suffer from its associated hearing loss and it is the most common cause of pediatric hearing loss in developing countries. There is a need for nonsurgical treatment due to a worldwide lack of resources. In this study, we show that EGF ligand shedding is essential for tympanic membrane healing as it's inhibition, with KB-R7785, leads to chronic perforation in 87.9% (n=58) compared with 0% (n=20) of controls. We then show that heparin binding-EGF-like growth factor (5 μg/mL), which acts to shed EGF ligands, can regenerate chronic perforations in mouse models with 92% (22 of 24) compared with 38% (10 of 26), also with eustachian tube occlusion with 94% (18 of 19) compared with 9% (2 of 23) and with CSOM 100% (16 of 16) compared with 41% (7 of 17). We also show the nonototoxicity of this treatment and its hydrogel delivery vehicle. This provides preliminary data for a clinical trial where it could be delivered by nonspecialist trained healthcare workers and fulfill the clinical need for a nonsurgical treatment for chronic tympanic membrane perforation and CSOM.
我们旨在探讨表皮生长因子(EGF)配体脱落在鼓膜伤口愈合中的作用,并研究其调控在慢性鼓膜穿孔组织工程中的转化应用。慢性化脓性中耳炎(CSOM)是一种感染性慢性鼓膜穿孔。全球多达2亿人受其相关听力损失影响,它是发展中国家儿童听力损失的最常见原因。由于全球资源匮乏,需要非手术治疗方法。在本研究中,我们表明EGF配体脱落对鼓膜愈合至关重要,因为用KB-R7785抑制它会导致87.9%(n = 58)的慢性穿孔,而对照组为0%(n = 20)。然后我们表明,可促使EGF配体脱落的肝素结合表皮生长因子样生长因子(5μg/mL),在小鼠模型中可使慢性穿孔再生,成功率为92%(24只中的22只),而对照组为38%(26只中的10只);咽鼓管阻塞模型中成功率为94%(19只中的18只),而对照组为9%(23只中的2只);CSOM模型中成功率为100%(16只中的16只),而对照组为41%(17只中的7只)。我们还证明了这种治疗方法及其水凝胶递送载体无耳毒性。这为一项临床试验提供了初步数据,在该试验中,它可以由未经专门培训的医护人员进行给药,满足慢性鼓膜穿孔和CSOM非手术治疗的临床需求。